The Mission of CGTLive™ is to deliver highly relevant, quality information about cell, gene, regenerative, and engineered medicines to healthcare professionals in order to facilitate the best patient care possible. CGTLive™ offers an independent, comprehensive digital platform that covers practice-changing news and insight directly from top medical conferences and researchers. The platform is intended for busy healthcare professionals who are considering or currently treating patients with The Mission of CGTLive™ is to deliver highly relevant, quality information about cell, gene, regenerative, and engineered medicines.
The news platform offers an in-depth look at the multitude of new products and procedures in development with ever-expanding targets and mechanisms, to help provide clarity during an unprecedented time of growing demand for expertise. The CGTLive™ platform connects visitors with the most up-to-date clinical trial results, FDA updates and approvals, practice-changing research, expert insight, and more. Additionally, through a unique mix of video editorial, CGTLive™ offers dynamic discussions with authoritative insights, opinions, and perspectives on critical issues facing today's healthcare professionals.
CGTLive™ delivers direct access to expert insight to improve the lives of patients with genetic disorders and targetable cancers, such as lymphoma, Duchenne muscular dystrophy, spinal muscular atrophy, lysosomal storage disorders, retinitis pigmentosa, GM1 and GM2 gangliosidosis, mucopolysaccharidosis, sickle cell anemia, hemophilia, and much more.